Insight, China's Pharmaceutical Industry

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has...

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

Fineline Cube Jul 17, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026

Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI),...

Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Fineline Cube Jul 17, 2026

Novartis AG (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has granted...

Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Fineline Cube Jul 17, 2026

Shionogi & Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

Fineline Cube Jul 17, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...

Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026

Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through...

Others

DP Technology, Excalipoint Therapeutics Launch AI Antibody Discovery Platform Through Strategic Partnership Focused on T-Cell Engagers

Fineline Cube Jul 17, 2026

DP Technology and Excalipoint Therapeutics announced a strategic partnership to co-develop a dedicated AI Antibody...

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical...

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026

Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial...

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Fineline Cube Jul 16, 2026

Boehringer Ingelheim reported continued strong sales growth in the first half of 2026 (H1 2026),...

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026

China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier...

Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Fineline Cube Jul 16, 2026

Harbour BioMed (HKG: 2142) and Kelun-Biotech (HKG: 6990) announced today that the Investigational New Drug...

Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Fineline Cube Jul 16, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and...

Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Fineline Cube Jul 16, 2026

Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of...

Company Drug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

Fineline Cube Jul 16, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that the Phase...

Company Drug

China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD

Fineline Cube Jul 16, 2026

China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products...

Company Drug

Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data

Fineline Cube Jul 16, 2026

Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug...

Company Drug

Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment

Fineline Cube Jul 16, 2026

Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization...

Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Fineline Cube Jul 16, 2026

Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products...

Insight, China's Pharmaceutical Industry

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

DP Technology, Excalipoint Therapeutics Launch AI Antibody Discovery Platform Through Strategic Partnership Focused on T-Cell Engagers

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD

Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data

Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

You Missed

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins